An auditory distortion is the experience of perceived alterations in how audible noises present and structure themselves.
These distortions can manifest in many styles, but commonly take the form of echoes or murmurs which rise in the wake of each sound and are accompanied by fluctuating changes in speed and pitch. This can intensify up to the point where sounds are consistently followed by continuous reverberation, often rendering the original sound completely unrecognizable. However, it often quickly resets to base level and starts over if the source of noise is stopped or changed.
The experience of this effect can be broken down into three distinct levels of intensity. These are described and documented below:
- Mild - At the lowest level of intensity, auditory distortions consist of subtle and spontaneous reverberation, echo effects, and changes in pitch of noises within the external environment. They are fleeting, low in intensity, and easy to ignore.
- Distinct - At this level, auditory distortions consist of distinctly noticeable, spontaneous echo effects and changes in pitch attributed to noises within the external environment. They are long and drawn out and loud enough to become difficult to ignore.
- All-encompassing - At the highest level, auditory distortions become constant and impossible to ignore. The complexity of the resulting alterations quickly renders the original sound as unintelligible.
Auditory distortions are often accompanied by other coinciding effects such as auditory hallucinations, auditory acuity suppression, and auditory acuity enhancement. They are most commonly induced under the influence of moderate dosages of psychedelic compounds, such as LSD, 5-MeO-DiPT, and DMT. However, they can also occur less commonly under the influence of dissociatives such as ketamine, PCP, and nitrous.
The audio clip above demonstrates how it may sound to listen to a lecture while undergoing the experience of level 3 auditory distortions.
This audio clip denotes level 3 audio distortions in a forest setting.
Compounds within our psychoactive substance index which may cause this effect include:
Anecdotal reports which describe this effect within our experience index include:
- Experience: 36mg 4-AcO-DiPT - Truly, one for the psychedelic animals among us
- Experience: 5-EAPB (60mg) + 2-FMA (20mg) + 4-AcO-DMT (10mg) - Emotional catharsis
- Experience:1000 Morning Glory seeds - Rediscovering the Self
- Experience:100ug 1P-LSD - A Fear and loathing into Bliss
- Experience:225mg Pregabalin +Cannabis -Bliss and Serenity; a hedonistic evening
- Experience:250mg MDA / 250mg MDMA - unnecessarily large dosage
- Experience:300µg ETH-LAD - Turned Inside Out
- Experience:300µg LSD - Togetherness and the Silent Dusk
- Experience:3g mimosa / 2g syrian rue - I was the Universe's prophet
- Experience:40mg - Brothermind and the Forest's Hand
- Experience:4x 200ug tabs - You do not need to understand
- Experience:5.3g psilocybe cubensis - Dimensional Circumstance and the Fabric of Understanding
- Experience:5g Mushrooms - Failed attempt at a Terence Mckenna style trip.
- Experience:6g mimosa / 2.5 g syrian rue - Best cake I've had for a while
- Experience:LSD (400ug, Oral) - An afternoon in "a" garden
- Experience:Mushrooms and Snuff Films -- Trip Report (3.5 grams)
- Experience:Unknown Dose DOC (Insufflated) - Overdosing and Terifying Ego Death
- Experience:~150mg MDA(oral) - a case of mistaken identity
- Responsible use
- Subjective effects index
- Psychedelics - Subjective effects
- Dissociatives - Subjective effects
- Deliriants - Subjective effects
- ↑ 1.0 1.1 Carbonaro, T. M., Forster, M. J., Gatch, M. B. (March 2013). "Discriminative stimulus effects of N,N-diisopropyltryptamine". Psychopharmacology. 226 (2): 241–246. doi:10.1007/s00213-012-2891-x. ISSN 0033-3158.
- ↑ 2.0 2.1 2.2 Juszczak, G. R., Swiergiel, A. H. (1 January 2013). "Recreational Use of D-Lysergamide from the Seeds of Argyreia Nervosa , Ipomoea Tricolor, Ipomoea Violacea, and Ipomoea Purpurea in Poland". Journal of Psychoactive Drugs. 45 (1): 79–93. doi:10.1080/02791072.2013.763570. ISSN 0279-1072.
- ↑ Mehta, U. M., Naveen Kumar, C., Venkatasubramanian, G., Thirthalli, J. (January 2017). "Multimodal Sensory Distortions in Postpartum Exacerbation of Schizophrenia". Clinical Schizophrenia & Related Psychoses. 10 (4): 222–224. doi:10.3371/CSRP.MEKU.112013. ISSN 1935-1232.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Weinel, J. (3 March 2016). "Entoptic Phenomena in Audio : Categories of Psychedelic Electroacoustic Composition". Contemporary Music Review. 35 (2): 202–223. doi:10.1080/07494467.2016.1221633. ISSN 0749-4467.
- ↑ 5.0 5.1 5.2 5.3 Strassman, R. (2001). DMT: the spirit molecule: a doctor’s revolutionary research into the biology of near-death and mystical experiences. Park Street Press. ISBN 9780892819270.
- ↑ 6.0 6.1 6.2 6.3 N. Stanciu, C., M. Penders, T. (1 June 2016). "Hallucinogen Persistent Perception Disorder Induced by New Psychoactive Substituted Phenethylamines; A Review with Illustrative Case". Current Psychiatry Reviews. 12 (2): 221–223.
- ↑ 7.0 7.1 Espiard, M.-L., Lecardeur, L., Abadie, P., Halbecq, I., Dollfus, S. (August 2005). "Hallucinogen persisting perception disorder after psilocybin consumption: a case study". European Psychiatry. 20 (5–6): 458–460. doi:10.1016/j.eurpsy.2005.04.008. ISSN 0924-9338.
- ↑ 8.0 8.1 Shulgin, A., Shulgin, A. (1997). TIHKAL: The Continuation. Transform Press.
- ↑ Strassman, R. J., Qualls, C. R., Berg, L. M. (May 1996). "Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans". Biological Psychiatry. 39 (9): 784–795. doi:10.1016/0006-3223(95)00200-6. ISSN 0006-3223.
- ↑ Meatherall, R., Sharma, P. (1 July 2003). "Foxy, a Designer Tryptamine Hallucinogen*". Journal of Analytical Toxicology. 27 (5): 313–317. doi:10.1093/jat/27.5.313. ISSN 1945-2403.
- ↑ Mowry, M., Mosher, M., Briner, W. (September 2003). "Acute Physiologic and Chronic Histologic Changes in Rats and Mice Exposed to the Unique Hallucinogen Salvinorin A". Journal of Psychoactive Drugs. 35 (3): 379–382. doi:10.1080/02791072.2003.10400021. ISSN 0279-1072.
- ↑ Leake, C. D. (21 February 1972). "Hallucinogenic Drug Reaction—MDA". JAMA: The Journal of the American Medical Association. 219 (8): 1069. doi:10.1001/jama.1972.03190340073029. ISSN 0098-7484.
- ↑ Hillhouse, T. M., Porter, J. H., Negus, S. S. (1 May 2014). "Reply to: Rapid antidepressant effects and abuse liability of ketamine". Psychopharmacology. 231 (9): 2043–2044. doi:10.1007/s00213-014-3544-z. ISSN 1432-2072.
- ↑ Oye, I., Paulsen, O., Maurset, A. (March 1992). "Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors". The Journal of Pharmacology and Experimental Therapeutics. 260 (3): 1209–1213. ISSN 0022-3565.